Table 2.

Tumor Characteristics and Laboratory Results

Variable	Xi’an, China (N = 786)	Freiburg, Germany (N = 407)	Menofia, Egypt (N = 391)	Hannover, Germany (N = 356)	Hong Kong 1 (N = 140)	Hong Kong 2 (N = 242)	Bologna, Italy (N = 234)	Ogaki, Japan (N = 613)	Amsterdam, NL (N = 138)	Pamplona, Spain (N = 85)	Birmingham, UK (N = 167)	Liverpool, UK (N = 132)	London, UK 1 (N = 114)	London, UK 2 (N = 84)	Nottingham, UK (N = 41)	Klagenfurt, Austria (N = 220)	Multicenter* (N = 471)
Solitary tumors, n (%)	396 (51.2), n = 774	132 (32.5), n = 406	161 (41.2), n = 391	77 (21.8), n = 353	59 (42.5), n = 139	82 (33.9), n = 242	108 (46.2), n = 234	190 (31.1), n = 612	42 (30.4), n = 138	27 (31.8), n = 85	59 (36.7), n = 161	63 (47.7), n = 132	48 (42.5), n = 113	30 (35.7), n = 84	18 (43.9), n = 41	73 (33.2), n = 220	107 (27.3), n = 392
Tumor size (cm)	8.5 (5.5, 11.8), n = 741	5.0 (3.2, 7.6), n = 407	4.5 (3.4, 5.9), n = 391	4.8 (3.1, 7.6), n = 329	5.9 (3.8, 10), n = 136	6.3 (4, 10), n = 230	3 (1.9, 4.3), n = 234	3.4 (2.2, 5.1), n = 564	5.0 (3.9, 6.8), n = 137	6 (3.3, 9.0), n = 79	5.1 (4.0, 7.9), n = 154	4.6 (3.3, 6.8), n = 132	5.0 (3.2, 7.3), n = 109	3.8 (2.1, 6.4), n = 84	5.0 (3.5, 10.7), n = 41	4.0 (3.0, 6.3), n = 220	3.5 (2.2, 5.8), n = 471
VI, n (%)	242 (30.8), n = 786	20 (4.9), n = 407	0 (0), n = 436	42 (11.9), n = 352	14 (10.0), n = 140	34 (14.1), n = 242	2 (0.9), n = 234	168 (27.5), n = 612	8 (5.8), n = 138	12 (14.1), n = 85	47 (28.1), n = 167	5 (3.8), n = 131	7 (6.2), n = 113	0 (0)	4 (9.8), n = 41	0 (0)	44 (9.3), n = 471
Baseline ALBI grade	n = 784	n = 407	n = 391	n = 355	n = 140	n = 242	n = 234	n = 612	n = 124	n = 75	n = 167	n = 132	n = 97	n = 82	n = 41	n = 220	n = 389
1	337 (43.0)	128 (31.5)	89 (22.8)	95 (26.8)	35 (25.0)	94 (38.8)	58 (24.8)	81 (13.2)	66 (53.2)	17 (22.7)	78 (46.7)	58 (43.9)	28 (28.9)	35 (42.7)	5 (12.2)	51 (23.2)	124 (31.9)
2	434 (55.4)	244 (60.0)	262 (67.0)	230 (64.8)	94 (67.1)	135 (55.8)	158 (67.5)	434 (70.9)	48 (38.7)	46 (61.3)	87 (52.1)	71 (53.8)	60 (61.9)	43 (52.4)	31 (75.6)	150 (68.2)	144 (37.0)
3	13 (1.7)	35 (8.6)	40 (10.2)	30 (8.5)	11 (7.9)	13 (5.4)	18 (7.7)	97 (15.9)	10 (8.1)	12 (16.0)	1 (1.2)	3 (2.3)	9 (9.3)	4 (4.9)	5 (12.2)	19 (8.6)	121 (31.1)
Baseline ALBI score	−2.50 (0.5), n = 784	−2.26 (0.6), n = 407	−2.15 (0.6), n = 391	−2.21 (0.6), n = 355	−2.22 (0.5), n = 140	−2.35 (0.5), n = 242	−2.21 (0.5), n = 234	−1.97 (0.6), n = 612	−2.46 (0.6), n = 124	−2.07 (0.6), n = 75	−2.48 (0.5), n = 167	−2.52 (0.5), n = 132	−2.24 (0.7), n = 97	−2.42 (0.5), n = 82	−2.01 (0.5), n = 41	−2.19 (0.5), n = 220	−1.98 (−3.08, −1.24), n = 389
Baseline AFP (ng/mL)	356.2 (14.2, 3650.5), n = 776	46.7 (6.7, 472.2), n = 366	79 (12.1, 49 7), n = 391	44 (7, 391), n = 323	89.5 (9, 1356.5), n = 140	126.5 (16, 2300), n = 242	15 (5, 58), n = 191	43 (12, 410), n = 579	28 (5.5, 305.5), n = 128	8.3 (4, 659.7), n = 81	60 (6, 1287), n = 163	10.5 (3, 157.5), n = 100	87.3 (7.1, 1206), n = 102	73.6 (7.5, 469), n = 79	32.5 (4, 546.5), n = 40	26.6 (6, 290.1), n = 219	31.5 (8, 236), n = 466
Baseline albumin (g/L)	39 (5.4), n = 784	36 (6.1), n = 407	35 (5.8), n = 391	35 (5.9), n = 355	35 (5.2), n = 140	37 (5.2), n = 242	37 (5.1), n = 234	33 (6.1), n = 612	38 (5.6), n = 127	35 (6.0), n = 76	38 (5.2), n = 167	39 (4.7), n = 132	37 (7.0), n = 106	38 (5.3), n = 83	33 (4.7), n = 41	36 (5.4), n = 220	32.7 (23.4, 44.8), n = 389
Baseline bilirubin (µmol/L)	16.7 (11.7, 22.6), n = 784	17.1 (12.0, 25.7), n = 407	18.8 (13.7, 25.7), n = 391	15 (10, 24), n = 356	14 (9, 22), n = 140	17 (11, 24), n = 242	21.6 (14.0, 36.9), n = 234	15.4 (11.1, 23.9), n = 612	16 (8, 26), n = 127	27.7 (15. 6, 42.5), n = 84	14 (9, 24), n = 167	14 (9.5, 23), n = 132	20 (14, 32), n = 97	17 (12, 25), n = 82	15 (10, 22), n = 41	21.6 (14.4, 32.3), n = 220	13.7 (10.3, 21), n = 471
Baseline AST (IU/L)	50 (35, 75.5), n = 784	65 (43, 101), n = 407	65 (46, 93), n = 391	N/A	N/A	N/A	N/A	N/A	53 (35, 92), n = 126	N/A	51 (35, 84), n = 167	N/A	N/A	68.5 (44, 107.5), n = 80	51.5 (37.5, 76), n = 20	52 (34.5, 80), n = 220	53 (36, 75), n = 449
Baseline platelets (× 109)	128 (81, 185), n = 786	155 (108, 221), n = 407	N/A	N/A	155 (91, 240), n = 138	162 (111, 252), n = 125	N/A	102 (69, 147), n = 500	142 (106, 195), n = 126	110 (76, 165), n = 85	N/A	N/A	N/A	130 (82, 202), n = 83	154 (110.5, 231.5), n = 40	117 (82, 173.5), n = 220	124 (85, 178), n = 392
Baseline INR	1.1 (1.0, 1.2), n = 778	1.1 (1.0, 1.2), n = 407	1.2 (1.1, 1.3), n = 391	N/A	1.1 (1.1, 1.2), n = 140	0.9 (0.9, 1.0), n = 242	1.3 (1.1, 1.4), n = 234	N/A	1.1 (1.1, 1.2), n = 122	1.2 (1.0, 1.2), n = 77	1.1 (1.0, 1.2), n = 167	1.1 (1.0, 1.2), n = 132	1.2 (1.1, 1.4), n = 103	1.2 (1.1, 1.3), n = 83	1.0 (0.9, 1.1), n = 41	N/A	1.1 (1.1, 1.2), n = 350
Baseline creatinine	80 (68, 93), n = 781	79.6 (61.9, 93.7), n = 406	72.5 (61.9, 96.4), n = 391	N/A	83 (72.5, 98.5), n = 140	N/A	N/A	N/A	76 (64, 91), n = 127	79.6 (70.7, 93.7), n = 82	87 (76, 101), n = 167	84 (73, 98), n = 132	87 (74, 99), n = 106	N/A	73 (61, 82), n = 41	80.4 (68.1, 96.4), n = 220	N/A
Response after first TACE	n = 786	n = 407	n = 390	N/A	N/A	N/A	n = 234	N/A	n = 105	N/A	N/A	N/A	N/A	N/A	n = 39	n = 212	n = 461
CR	133 (16.9)	6 (1.5)	167 (42.8)	N/A	N/A	N/A	125 (53.4)	N/A	18 (17.1)	N/A	N/A	N/A	N/A	N/A	7 (18.0)	11 (5.2)	158 (34.3)
PR	203 (25.8)	57 (14.0)	150 (38.5)	N/A	N/A	N/A	96 (41.0)	N/A	54 (51.4)	N/A	N/A	N/A	N/A	N/A	9 (23.1)	68 (32.1)	110 (23.9)
SD	268 (34.1)	230 (56.5)	49 (12.6)	N/A	N/A	N/A	2 (0.9)	N/A	11 (10.5)	N/A	N/A	N/A	N/A	N/A	10 (25.6)	116 (54.7)	80 (17.4)
PD	182 (23.2)	114 (28.0)	24 (6.2)	N/A	N/A	N/A	11 (4.7)	N/A	22 (21.0)	N/A	N/A	N/A	N/A	N/A	13 (33.3)	17 (8.0)	113 (24.5)

^*Centers involved London (UK), Osaka (Japan), Seoul (Korea), and Novara (Italy).

Abbreviations: AST, aspartate transaminase; ECOG, Eastern Cooperative Oncology Group; N/A, not applicable; NL, the Netherlands; UK, United Kingdom.